Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644817 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1TDP1MEN1MAPT | |
| SCHEMBL13239929 | 0.72 | CTSD (0.31) | — | |
| SCHEMBL9175310 | 0.68 | DUSP3 (0.52) | KDM4EALDH1A1TDP1MEN1MAPT | |
| SCHEMBL10053454 | 0.68 | KDM4E (0.30) | KDM4EALDH1A1TDP1MEN1MAPT | |
| SCHEMBL3413343 | 0.67 | CDC25A (0.37) | — | |
| SCHEMBL17532554 | 0.67 | CDC25A (0.38) | KDM4EALDH1A1TDP1MEN1MAPT | |
| SCHEMBL12619913 | 0.66 | — | — | |
| SCHEMBL840081 | 0.65 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL10029595 | 0.65 | — | — | |
| SCHEMBL15982100 | 0.65 | KDM4E (0.36) | KDM4EALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| US-10767030-B2 | Optical article and optical filter comprising same | LMS CO., LTD. | 2020-09-08 | — | — | US | disclosed |
| US-20190055375-A1 | OPTICAL ARTICLE AND OPTICAL FILTER COMPRISING SAME | LMS Co.,Ltd. (KR) | 2019-02-21 | — | — | US | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-2917218-B1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150045545-A1 | SORBENT COMPRISING ON ITS SURFACE AN AROMATIC RING SYSTEM HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | INSTRACTION GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20140343261-A1 | SORBENT COMPRISING ON ITS SURFACE AN ALIPHATIC UNIT HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | INSTRACTION GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140243512-A1 | SORBENT COMPRISING AN AROMATIC RING SYSTEM ON ITS SURFACE FOR THE PURIFICATION OF ORGANIC MOLECULES | INSTRACTION GMBH (DE) | 2014-08-28 | — | — | US | disclosed |
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | KDM4E 1929/4885ALDH1A1 2912/4885TDP1 4400/4885 |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | KDM4E 2626/4885ALDH1A1 1440/4885TDP1 4783/4885 |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, TDP1 | KDM4E 1619/4885ALDH1A1 1090/4885TDP1 3/4885 |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | KDM4E 1882/4885ALDH1A1 2051/4885TDP1 4598/4885 |
| US-20150045545-A1 | SORBENT COMPRISING ON ITS SURFACE AN AROMATIC RING SYSTEM HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | ABCG2, SORBS1, MAOA | KDM4E 515/4885ALDH1A1 200/4885TDP1 2964/4885 |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | KDM4E 2512/4885ALDH1A1 563/4885TDP1 2550/4885 |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | CHP1, RYR2, CANX | KDM4E 3080/4885ALDH1A1 4482/4885TDP1 1971/4885 |
| US-20140343261-A1 | SORBENT COMPRISING ON ITS SURFACE AN ALIPHATIC UNIT HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES | EPCAM, SLCO2B1, SLCO4C1 | KDM4E 1352/4885ALDH1A1 74/4885TDP1 3336/4885 |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | KDM4E 2154/4885ALDH1A1 2398/4885TDP1 4053/4885 |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | KDM4E 1619/4885ALDH1A1 1090/4885TDP1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.